Medical Developments International shares on watch following Penthrox update

The Medical Developments International Ltd (ASX:MVP) share price will be on watch today after the release of a Penthrox update…

| More on:
a woman

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Medical Developments International Ltd (ASX: MVP) share price will be on watch this morning follow a positive announcement relating to its Penthrox product.

What is Penthrox?

Penthrox, or the green whistle, is a fast onset, non-opioid analgesic. It is indicated for pain relief by self-administration in patients with trauma and those requiring analgesia for surgical procedures.

It has been used safely and effectively for over 40 years in Australia with more than 5 million units sold.

In recent times the company has been looking at expanding its use, hence today's announcement.

What did Medical Developments International announce?

This morning the healthcare company announced that data across 11 abstracts of studies conducted throughout Europe have demonstrated multiple positive results of Penthrox.

This includes Penthrox demonstrating superiority over intravenous (IV) morphine, paracetamol, ketoprofen, and NSAIDS within a trauma setting.

It also found that Penthrox added to the standard of care (SoC) demonstrates superiority over SoC plus a placebo within a trauma setting.

The product was also successful in dislocation injuries. Its use resulted in reduced time spent in the Emergency Departments, which improves the patient experience and reduces crowding.

The release explains that other studies confirmed previously published data. This includes Penthrox being an efficacious, well tolerated/safe and rapidly acting analgesic in trauma settings.

Another positive was that the studies commonly reported that Penthrox exceeded patient/clinician expectations and/or resulted in a high degree of treatment satisfaction from patients and health care professionals.

The company's CEO, John Sharman, was delighted with the study results.

He said: "We are delighted with the results of these recent European clinical trials demonstrating superiority of Penthrox over Standard of Care treatments (intravenous (IV) morphine, IV paracetamol, ketoprofen or NSAIDS) within the acute trauma setting. This reinforces the global potential for Penthrox as a simple, fast and effective non-opioid pain medication."

James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns shares of Medical Developments International Limited. The Motley Fool Australia has recommended Medical Developments International Limited. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Share Market News

A woman in a business suit sits at her desk with gold bars in each hand while she kisses one bar with her eyes closed. Her desk has another three gold bars stacked in front of her. symbolising the rising Northern Star share price
Gold

Titan Minerals shares leaping 14% on Wednesday on 'spectacular' gold results

Investors are piling into Titan Minerals shares today following 'phenomenal' gold exploration results.

Read more »

Male hands holding Australian dollar banknotes, symbolising dividends.
Share Market News

BlueScope returns $438m to shareholders with special dividend

BlueScope will return $438 million to shareholders via a $1 per share special dividend after selling major assets.

Read more »

Man looking happy and excited as he looks at his mobile phone.
Broker Notes

Want silver exposure? Morgans says this ASX silver stock is a buy

The broker thinks this could be a high-risk, high-reward option for investors.

Read more »

CEO of a company talking.
Share Market News

Deep Yellow welcomes new CEO as part of ongoing uranium growth strategy

Deep Yellow has set a start date for new CEO Greg Field, with project development remaining on track as part…

Read more »

A young man goes over his finances and investment portfolio at home.
Broker Notes

What is Bell Potter saying about this high-flying ASX 200 share after its 140% rise?

Bell Potter has been looking at the metal detector manufacturer's performance this financial year.

Read more »

Cheerful businessman with a mining hat on the table sitting back with his arms behind his head while looking at his laptop's screen.
Share Market News

Monadelphous secures $300m Rio Tinto contract

Monadelphous secures a $300 million Rio Tinto contract, strengthening its maintenance services position in Australia’s resources sector.

Read more »

a uranium-fuelled mushroom shaped cloud explosion surrounded by a circle of rainbow light with a symbol of an atom to one side of it.
Opinions

What's next for the best-performing ASX 200 stock of 2025?

This ASX stock boomed in 2026.

Read more »

Woman thinking in a supermarket.
Dividend Investing

I'd buy this ASX dividend stock in any market

This business is a great option for dividends.

Read more »